Germany-based healthcare company Fresenius SE confirmed that it is in talks to acquire U.S. generic-pharmaceuticals manufacturer, Akorn Inc.
Illinois-based Akorn had sales of $1.1 billion last year. Akorn makes branded and generic versions of ophthalmic, injectable and non-injectible drugs. The niche drugmaker has global manufacturing facilities in Illinois, New York, New Jersey, Switzerland and India.
The Akorn purchase would compliment Fresenius' medicines division, which specializes in intravenous drugs, and accounts for about a fifth of the company’s revenue.
Read the Bloomberg coverage
